Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV. PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy.

Detailed Description
-----------------
OBJECTIVES: Primary To quantify HIV-1 persistence in prospectively collected samples from patients on suppressive antiretroviral therapy undergoing chemotherapy for Hodgkin lymphoma. OUTLINE: This is a multicenter study. Blood samples are collected before, during, and after treatment for lymphoma for HIV-1 RNA levels using standard and single copy assays and HIV-1 DNA quantification (peripheral blood mononuclear cells). After completion of treatment, patients are followed up periodically for up to 2 years.

Official Title
-----------------
Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)

Conditions
-----------------
Lymphoma, Nonneoplastic Condition

Intervention / Treatment
-----------------
* Genetic: DNA analysis
* Genetic: RNA analysis
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: HIV-1 infection, as documented by a rapid HIV test or any FDA-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry Documentation may be serologic (positive ELISA and positive western blot), or other federally approved licensed HIV diagnostic test Prior documentation of HIV seropositivity is acceptable Diagnosis of untreated Hodgkin lymphoma and participation in the parent protocol SWOG-S0816, A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging. PATIENT CHARACTERISTICS: No psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator Willing to provide serial blood samples PRIOR CONCURRENT THERAPY: See Disease Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: DNA analysis|nan|
|Genetic: RNA analysis|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in viral load from baseline to each subsequent time point | Time frame for outcome measures dependent on study calendar for parent protocol, S0816, which varies by subject's PET scan status. | Baseline, after each cycle of treatment, restaging, treatment completion, year 1, year 2, study discontinuation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage III adult Hodgkin lymphoma, stage IV adult Hodgkin lymphoma, HIV infection